Drugs / Satricabtagene autoleucel
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06857786 | Mar 2025 → Jun 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Peking University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05911217 | Jul 2023 → Dec 2026 expected | malignant pancreatic neoplasm | CARsgen Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT03874897 | Mar 2019 → Mar 2021 | neoplasm | Peking University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04581473 | Oct 2020 → Oct 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm | CARsgen Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04404595 | Oct 2020 → Jun 2025 overdue | gastric cancer, malignant pancreatic neoplasm | CARsgen Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Satricabtagene autoleucel | “Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in...” PMID 40460847 ↗ May 20251“Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2” PMID 38830992 ↗ Jun 2024 |
| Known as | CAR-CLDN18.2 T-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03874897 ↗ |
| Known as | CT041 | “Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2” PMID 38830992 ↗ Jun 2024 |
| Known as | satri-cel | “Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in...” PMID 40460847 ↗ May 20251“Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2” PMID 38830992 ↗ Jun 2024 |
| Known as | Satricabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314708 ↗ |
| Modality | Cell therapy | “autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2” PMID 38830992 ↗ Jun 2024 |
| Route | Other | “CAR T cell infusion” PMID 41318814 ↗ Nov 2025 |
| Target | CLDN18 | “targeting CLDN18.2” PMID 38830992 ↗ Jun 2024 |